NEW YORK (GenomeWeb News) – Merck and Luminex said they will work together to develop a companion test for Merck's investigational BACE inhibitor for Alzheimer's disease, MK-8931.

The diagnostic, which will operate on Luminex's xMAP platform, will be used to stratify patients into clinical trials involving MK-8931. According to the companies, Luminex will be in charge of developing, garnering regulatory approval, and commercializing the companion test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.